VR1 antagonists (Evotec/Pfizer)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameVR1 antagonists (Evotec/Pfizer)
Drug Alias Namevanilloid receptor 1 antagonists (Renovis)VR1 antagonists (Renovis/Pfizer)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVanilloid receptor antagonists
TargetsTransient receptor potential cation channel subfamily V member 1
Therapy Area/IndicationsPain
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRenovis
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncRenovisEvotec SE
Active IndicationsN/A
Inactive IndicationsPain

Other Information

ATC CodeN/A
Related LinksN/A